SCHEMBL5954441

SCHEMBL5954441

CCNC(=O)c1ccc2nnc(Sc3ccc4nc(NC(=O)C5CC5)cn4n3)n2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.40
CSNK1D P48730 3/20 0.39
CSNK1E P49674 3/20 0.39
MET P08581 2/20 0.38
BRAF P15056 1/20 0.38
TTK P33981 1/20 0.37
RIPK1 Q13546 1/20 0.37
PDGFRB P09619 2/20 0.37
FLT1 P17948 2/20 0.37
AURKA O14965 1/20 0.37
KIT P10721 1/20 0.37
ABL1 P00519 1/20 0.37
CSF1R P07333 1/20 0.37
YES1 P07947 1/20 0.37
RET P07949 1/20 0.37
BCR P11274 1/20 0.37
PDGFRA P16234 1/20 0.37
FLT4 P35916 1/20 0.37
ABL2 P42684 1/20 0.37
DDR1 Q08345 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL253869 0.92 KDR (0.39) KDRCSNK1DCSNK1EMETBRAF
SCHEMBL5955121 0.91 KDR (0.39) KDRCSNK1DCSNK1EMETBRAF
SCHEMBL5955126 0.90 KDR (0.41) KDRCSNK1DCSNK1EMETBRAF
SCHEMBL248460 0.88 JAK1 (0.41) KDRCSNK1DCSNK1EMETBRAF
SCHEMBL252980 0.87 KDR (0.43) KDRCSNK1DCSNK1EMETBRAF
SCHEMBL253306 0.87 KDR (0.41) KDRCSNK1DCSNK1EMETBRAF
SCHEMBL5954136 0.87 KDR (0.42) KDRCSNK1DCSNK1EMETBRAF
SCHEMBL251983 0.85 KDR (0.43) KDRCSNK1DCSNK1EMETPDGFRB
SCHEMBL5955019 0.84 KDR (0.40) KDRCSNK1DCSNK1EMET
SCHEMBL5955305 0.84 KDR (0.40) KDRCSNK1DCSNK1EMETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178534-B2 cMET inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-05-15 US disclosed
US-8178534-B2 cMET inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-05-15 US disclosed
US-20100063054-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-11 US disclosed
US-20100063054-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-11 US disclosed
WO-2010019899-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063054-A1 cMET INHIBITORS CEPT1, LCAT, GNMT KDR 1387/4885CSNK1D 225/4885CSNK1E 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.